News

The authorisation was granted after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency reviewed the primary data from the vaccine’s Phase III

The study was led by Torri Metz of University of Utah Health and Rebecca Clifton of George Washington University’s Milken Institute School of Public Health. When compared to

The study aims to identify the types of lung cells targeted by the virus and the resulting reaction due to the infection. In some of the most severe

As per the agreement, Sanofi will manufacture 125 million doses of the Covid-19 vaccine in Europe. Initial supplies of vaccine are expected to come out of Sanofi’s facilities

As per the study which was published in the journal Cancer Research, the clinical trial showed positive results of the drug palbociclib in a specific type of triple

BIO 300 is Humanetics’ drug candidate which is expected to counteract and relieve not only severe and chronic inflammatory diseases but also radiation toxicities. The progressive pulmonary inflammation

The approval for Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) was based on the positive results from SYGMA 1 and SYGMA 2 Phase III trials, which evaluated the efficacy of the

Merck said that the review findings of the clinical trials showed that V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen

Through the expanded agreement, Humanigen will now gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority (BARDA) for the development of lenzilumab as